Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
MRK-740
Contact us for more batch information
MRK-740
Catalog No. T62957Cas No. 2387510-80-5
MRK-740 is a potent and selective inhibitor of PRDM9 histone methyltransferase.MRK-740 inhibits other histone methyltransferases and inhibits PRDM9-dependent H3K4 trimethylation.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $105 | In Stock | |
| 10 mg | $172 | In Stock | |
| 25 mg | $372 | In Stock | |
| 50 mg | $597 | In Stock | |
| 100 mg | $879 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $118 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MRK-740"
lutidinic acid
T2167499-80-9
lutidinic acid (2,4-Dicarboxypyridine) is an in vitro and in cell inhibitor, as well as a known inhibitor of the histone lysine demethylases.
- $29
Size
QTY
EML734
T79614
EML734 is a potent, selective inhibitor of PRMT7 and PRMT9, demonstrating inhibitory concentration 50 (IC50) values of 315 nM for PRMT7 and 0.89 μM for PRMT9.
- Inquiry Price
Size
QTY
MS9715
T79615
MS9715 is a potent and selective NSD3-targeting PROTAC, designed by leveraging BI-9321, which targets the PWWP1 domain of NSD3, in conjunction with an E3 ligase VHL ligand. This compound holds potential for research in NSD3-dependent cancer treatments [1].
- Inquiry Price
Size
QTY
MS8511 HCl
T63351LIn house
MS8511 HCl is a selective and potent covalent inhibitor of G9a/GLP that acts by targeting cysteine residues in the substrate binding site. MS8511 has anticancer activity and antiproliferative activity and reduces intracellular H3K9me2 levels.MS8511 can be used to study a wide range of cancers including brain, breast, and ovarian cancers .
- $195
Size
QTY
EML741
T111852328074-38-8
EML741 also inhibits DNMT1 (IC50, 3.1 μM), with no effect on DNMT3a or DNMT3b. EML741 exhibits low cell toxicity, and is membrane permeable and blood-brain barrier penetrated. EML741 is a histone lysine methyltransferase G9a/GLP inhibitor, with an IC50 of 23 nM, Kd of 1.13 μM for G9a.
- $1,520
Size
QTY
WDR5-0102
T67947824960-50-1
WDR5-0102 is a compound that inhibits the WDR5-MLL1 interface (K dis = 7 μM, K d = 4 μM), selectively reducing MLL1 HMT activity without affecting the human H3K4 methyltransferase SETD7 or other HMTs, including G9a, EHMT1, SUV39H2, SETD8, PRMT3, and PRMT5.
- $70
Size
QTY
M‑89
T119252363165-42-6
M-89, a highly potent and specific inhibitor of the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction, exhibits a Kd of 1.4 nM for menin binding. This compound holds potential for treating MLL leukemia.
- $169
Size
QTY
CM-272
T71941846570-31-7
CM-272 is a dual G9a/DNA methyltransferases (DNMTs) inhibitor.
- $67
Size
QTY
MI-2-2
T280361454920-20-7
MI-2-2 is an inhibitor of bivalent protein-protein interaction between menin and MLL with an IC50 of 46 nM. MI-2-2 binds to menin with Kd of 22 nM.
- $58
Size
QTY
UNC0638
Cited
T32571255580-76-7
UNC0638 is an inhibitor of β-protein lysine methyltransferases G9a(IC50<15 nM) and GLP(IC50=19 nM) with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets.
- $54
Size
QTY
CitedProduct Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | MRK-740 is a potent and selective inhibitor of PRDM9 histone methyltransferase.MRK-740 inhibits other histone methyltransferases and inhibits PRDM9-dependent H3K4 trimethylation. |
| In vitro | After 24 hours of treatment, MRK-740 (3 μM) does not affect the growth of HEK293T cells at IC90, but some toxicity is observed at 10 μM. MRK-740 serves as an equivalent inhibitor of H3K4 methylation in MCF7 cells. In cells, MRK-740 selectively and directly inhibits H3K4 methylation at endogenous PRDM9 target sites[1]. |
| Molecular Weight | 464.56 |
| Formula | C25H32N6O3 |
| Cas No. | 2387510-80-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (64.58 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.